On September 28, Moderna, Inc. fell 3.2% in pre-market trading, trading at $192.75/share, with turnover of $5.1249 million. The stock retreated from a recent high of $202.67 after surging approximately 29% over the prior week.

The pullback comes as Moderna's stock price has significantly overshot Wall Street consensus targets. According to analyst polls, the average rating remains Hold with a mean price target around $112.72, well below the current trading level. Notably, Rothschild & Co Redburn recently downgraded the stock to Sell with an $81 price target, while even bullish Argus Research's Buy-rated $180 target sits below Friday's close of $198.88. Meanwhile, the stock's implied volatility stands at 86.98% with an IV percentile of 74.90%, indicating elevated options pricing.

The recent rally was driven by Moderna's personalized mRNA cancer vaccine intismeran autogene achieving positive Phase 3 INTerpath-001 results in melanoma. Complete data will be presented at the ESMO annual meeting on October 24. Year-to-date, Moderna shares have gained over 560%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)